Cardax, Inc. Announces Sales Results for the Second Quarter of 2018
August 13, 2018 at 05:00 pm EDT
Share
Cardax, Inc. announced sales results for the second quarter of 2018. Revenues from sales of ZanthoSyn®, its premium astaxanthin dietary supplement for inflammatory health and longevity, increased more than four times, to $272,049 in Second Quarter 2018 from $66,237 in second quarter of 2017.
Revenues for the six-months ended June 30, 2018 also grew strongly to $585,359 from $174,227 for the same period in 2017. The results primarily reflect sales to GNC driven by the strong sell-through rate of ZanthoSyn® in Hawaii as well as an accelerating sales trend in California, Nevada, and New York. Sales were supported by over 1,000 high quality interactions with physicians and other health care professionals at conferences, meetings, and continuing medical education events.
Cardax, Inc. is a consumer health company focused on marketing ZanthoSyn, an astaxanthin dietary supplement for inflammatory health. It seeks to monetize CDX-101, the Company's pre-clinical pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, and CDX-301, the Company's pre-clinical pharmaceutical candidate for macular degeneration. CDX-101 is a proprietary astaxanthin prodrug that cleaves following oral administration and delivers astaxanthin to the bloodstream. Astaxanthin is a naturally occurring molecule with safe anti-inflammatory activity that supports cardiovascular health, metabolic health, liver health, joint health, and longevity. It intends to develop zeaxanthin pharmaceutical candidate, CDX-301, for macular degeneration. Zeaxanthin accumulates in the human eye through uptake by a retinal receptor, providing protection against blue light, oxidative damage, and related inflammation that occurs in macular degeneration.